Johnson & Johnson (JNJ)
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
You will want to build your portfolio the right way if you're going to make money with stocks over the long haul. You wouldn't build your house on a shaky foundation, would you?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
J&J Pauses Sales of Atrial Fibrillation Device, Stock Down
J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.
J&J pauses rollout of heart device in the US to investigate stroke risk
Johnson & Johnson said on Wednesday that it has temporarily paused the rollout of its Varipulse heart device in the United States, citing an abundance of caution as the company investigates four reported stroke events.
Johnson & Johnson: A Potential Beneficiary Of A Great Rotation
Johnson & Johnson's stagnant price and bond-like behavior make it an income investment, but a market shift could boost its appeal in 2025. Value stocks, including JNJ, may gain favor as growth stocks' earnings slow and proposed policies boost earnings in other sectors. JNJ's 3.41% dividend yield and attractive forward PE ratio of 13.5 offer potential upside if value stocks regain market attention.
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
Johnson & Johnson (JNJ) reachead $146.18 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.
2 Dividend Kings to Rule Them All in 2025
If history is any teacher, the best thing you can do with your money is buy dividend stocks.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Johnson & Johnson (JNJ) settling at $144.62, representing a +0.89% change from its previous close.
J&J Trading Near 52-Week Low: Should You Sell the Stock?
Those who own the stock may stay invested for some time as J&J looks optimistic about a better performance in 2025.
Johnson & Johnson Death Cross: Stock Stumbles Despite Pipeline Promise
Johnson & Johnson JNJ, the iconic healthcare giant known for its stable dividends and defensive appeal, has entered a bearish technical pattern: the Death Cross.
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723
Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.
